Memorial Sloan Kettering Cancer Center revealed novel mechanisms linking metabolism, gene mutations, and therapeutic resistance in cancers including intestinal and breast cancer. Adaptive Biotechnologies earned a Buy rating on its leading MRD testing in hematologic malignancies, emphasizing broad market potential. City of Hope received $23.7 million from ARPA-H to map lung cancer immunotherapy resistance biomarkers over six years. GeneCentric raised $8 million to launch GenomicsNext ctDNA liquid biopsy platform, advancing non-invasive cancer diagnostics. These efforts collectively enrich precision oncology with dynamic, multi-modal strategies for diagnosis and treatment.